Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA awards fast track status to Oncolytics Biotech's Reolysin for metastatic breast cancer

May 9, 2017

Regeneron enters agreements with Inovio and SillaJen for combination studies of REGN-2810

May 9, 2017

Seattle Genetics and Immunomedics terminate license agreement for sacituzumab govitecan

May 9, 2017

Immunocore identifies new ImmTAC lead molecule under collaboration with GSK

May 8, 2017

EC approves Merck & Co.'s Keytruda in classical Hodgkin's lymphoma

May 8, 2017

ADC Therapeutics enrolling patients in phase I trial of ADCT-502

May 5, 2017

ImMAGE Biotherapeutics begins repeat toxicology study for IMT-001

May 5, 2017

OncoMed initiates phase Ia study of OMP-313M32 in advanced solid tumors

May 5, 2017

Heat Biologics completes acquisition of Pelican Therapeutics

May 4, 2017

First patient dosed in first-in-human phase I/II trial of RGT-100

May 4, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...